Regeneron's new drug cuts heart rate spikes and helps patients feel better in a heart disease study.

REGN · Regeneron Pharmaceuticals Inc.

The AI's read

This gives Regeneron encouraging evidence for a possible new POTS treatment. The larger dose improved symptoms, but mild or moderate side effects affected more patients than with placebo. The smaller dose showed no clear benefit, and this Phase 2 study included only 82 patients.